Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RAF1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123625 | Oral cavity | EOLP | regulation of extrinsic apoptotic signaling pathway | 42/2218 | 151/18723 | 7.31e-08 | 2.61e-06 | 42 |
GO:000726522 | Oral cavity | EOLP | Ras protein signal transduction | 74/2218 | 337/18723 | 8.76e-08 | 3.09e-06 | 74 |
GO:001982713 | Oral cavity | EOLP | stem cell population maintenance | 38/2218 | 131/18723 | 9.10e-08 | 3.15e-06 | 38 |
GO:009719125 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway | 54/2218 | 219/18723 | 9.74e-08 | 3.36e-06 | 54 |
GO:004315423 | Oral cavity | EOLP | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 27/2218 | 78/18723 | 1.28e-07 | 4.22e-06 | 27 |
GO:009872713 | Oral cavity | EOLP | maintenance of cell number | 38/2218 | 134/18723 | 1.74e-07 | 5.61e-06 | 38 |
GO:200011723 | Oral cavity | EOLP | negative regulation of cysteine-type endopeptidase activity | 28/2218 | 86/18723 | 3.25e-07 | 9.60e-06 | 28 |
GO:004586125 | Oral cavity | EOLP | negative regulation of proteolysis | 72/2218 | 351/18723 | 1.96e-06 | 4.49e-05 | 72 |
GO:000166624 | Oral cavity | EOLP | response to hypoxia | 65/2218 | 307/18723 | 2.00e-06 | 4.55e-05 | 65 |
GO:003133324 | Oral cavity | EOLP | negative regulation of protein-containing complex assembly | 37/2218 | 141/18723 | 2.01e-06 | 4.57e-05 | 37 |
GO:007048224 | Oral cavity | EOLP | response to oxygen levels | 70/2218 | 347/18723 | 5.00e-06 | 1.02e-04 | 70 |
GO:003629324 | Oral cavity | EOLP | response to decreased oxygen levels | 66/2218 | 322/18723 | 5.31e-06 | 1.07e-04 | 66 |
GO:190204122 | Oral cavity | EOLP | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 18/2218 | 49/18723 | 6.01e-06 | 1.19e-04 | 18 |
GO:004510412 | Oral cavity | EOLP | intermediate filament cytoskeleton organization | 18/2218 | 51/18723 | 1.15e-05 | 2.00e-04 | 18 |
GO:004510312 | Oral cavity | EOLP | intermediate filament-based process | 18/2218 | 52/18723 | 1.56e-05 | 2.59e-04 | 18 |
GO:000862521 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway via death domain receptors | 24/2218 | 82/18723 | 1.73e-05 | 2.84e-04 | 24 |
GO:001095124 | Oral cavity | EOLP | negative regulation of endopeptidase activity | 52/2218 | 252/18723 | 4.21e-05 | 5.74e-04 | 52 |
GO:200123724 | Oral cavity | EOLP | negative regulation of extrinsic apoptotic signaling pathway | 26/2218 | 97/18723 | 4.30e-05 | 5.82e-04 | 26 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:001046624 | Oral cavity | EOLP | negative regulation of peptidase activity | 52/2218 | 262/18723 | 1.21e-04 | 1.34e-03 | 52 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0521010 | Cervix | CC | Colorectal cancer | 27/1267 | 86/8465 | 8.60e-05 | 5.57e-04 | 3.30e-04 | 27 |
hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
hsa052148 | Cervix | CC | Glioma | 24/1267 | 75/8465 | 1.51e-04 | 9.20e-04 | 5.44e-04 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAF1 | SNV | Missense_Mutation | | c.677T>A | p.Val226Asp | p.V226D | P04049 | protein_coding | tolerated(0.59) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAF1 | SNV | Missense_Mutation | rs730881004 | c.1814N>T | p.Ser605Phe | p.S605F | P04049 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
RAF1 | SNV | Missense_Mutation | | c.364N>G | p.Ile122Val | p.I122V | P04049 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-BH-A18S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAF1 | SNV | Missense_Mutation | | c.1819N>C | p.Glu607Gln | p.E607Q | P04049 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
RAF1 | SNV | Missense_Mutation | novel | c.1060N>T | p.Arg354Trp | p.R354W | P04049 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
RAF1 | insertion | Nonsense_Mutation | novel | c.1576_1577insAGGCTCAGGGCTGCTAGAATGTGATTAAAGC | p.Ser526LysfsTer6 | p.S526Kfs*6 | P04049 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
RAF1 | insertion | In_Frame_Ins | novel | c.1724_1725insAAAGCAGGGGCCCAGCCCCAGCTGTTG | p.Lys575_Asn576insLysGlnGlyProSerProSerCysTrp | p.K575_N576insKQGPSPSCW | P04049 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAF1 | insertion | Frame_Shift_Ins | novel | c.296_297insTGTTGAAGTGCAAATCTTTGAAG | p.Arg100ValfsTer21 | p.R100Vfs*21 | P04049 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
RAF1 | insertion | In_Frame_Ins | novel | c.1697_1698insTTTTAAAGTAAT | p.Ala566_Ser567insPheLysValIle | p.A566_S567insFKVI | P04049 | protein_coding | | | TCGA-BH-A0BA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
RAF1 | insertion | Frame_Shift_Ins | novel | c.1696_1697insTTACCTC | p.Ala566ValfsTer8 | p.A566Vfs*8 | P04049 | protein_coding | | | TCGA-BH-A0BA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | SORAFENIB | SORAFENIB | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | sorafenib | SORAFENIB | 20124951,28362716 |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | REGORAFENIB | REGORAFENIB | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 404859105 | | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | TRAMETINIB | TRAMETINIB | 30835257 |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL3545296 | ARQ-736 | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL1200485 | SORAFENIB TOSYLATE | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | SORAFENIB | SORAFENIB | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 328083491 | SB590885 | |
5894 | RAF1 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | XL281 | | |